Cannabis Report
Lithium
Home > Boards > US OTC > Biotechs >

Galectin Therapeutics Inc. (GALT)

GALT RSS Feed
Add GALT Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 8/18/2018 10:24:20 AM - Followers: 79 - Board type: Free - Posts Today: 0

Galectin Therapeutics is a biotechnology company focused on discovery and development. We apply our leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on our unique carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function.

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.

Galectin Therapeutics leverages extensive scientific and development expertise as well as established relationships with outside sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer immunotherapy.
 

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Though we do not have any current marketed products, our research and development programs, designed to ultimately help patients and their physicians, are focused on:

 

Fibrosis

 

Fibrosis is the development of excess fibrous connective tissue in an organ when exposed to a chronic disease. The longer the disease affects the organ, the more fibrous tissue is deposited and this ultimately results in the failure of the organ. Galectin Therapeutics’ drug candidates provide a promising and exciting new approach for the treatment of fibrotic diseases, including liver, lung and kidney fibrosis. Significant unmet need exists for treatment options in fibrosis. For example, there are currently no approved medical treatments available for the millions of patients in the U.S. who have non-alcoholic steatohepatitis with advanced fibrosis – commonly known as fatty liver disease. Learn about fibrosis and our research in this area including galectin effects on liver fibrosis, lung fibrosis and kidney fibrosis.

 

Cancer

 

Cancer harms the body when damaged cells divide uncontrollably to form lumps or masses of tissue called tumors. Research shows the potential for galectin inhibition to play an important role in cancer therapy, particularly tumor immunotherapy – an emerging treatment that enhances the activity of the immune system against cancer cells. There are more than 100 types of cancers, and for many of these cancers, few treatment options exist. Our drug candidates provide a new and complimentary approach to other drugs on the market for the treatment of cancer. Learn more about cancer and immunotherapy.

 

Cannabis Report
Lithium
GALT
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GALT News: Galectin Therapeutics Reports 2018 Second Quarter Financial Results and Provides Business Update 08/14/2018 08:00:00 AM
GALT News: Current Report Filing (8-k) 08/14/2018 07:57:32 AM
GALT News: Quarterly Report (10-q) 08/14/2018 07:50:58 AM
GALT News: Securities Registration Statement (simplified Form) (s-3) 07/27/2018 04:36:33 PM
GALT News: Galectin Therapeutics Receives Patent for GR-MD-02 Patent for Method and Treatment of Pulmonary Fibrosis 06/27/2018 08:00:00 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#3425   https://msmoneymoves.com/august-2/ buckysherm 08/18/18 10:24:20 AM
#3424   https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771079/ buckysherm 08/16/18 01:47:16 PM
#3423   I was looking for an entry point when jimmy667 08/15/18 10:44:10 AM
#3422   https://oregon.providence.org/news-and-events/news/2014/10/dr-urba-honored-as-ca buckysherm 08/14/18 02:26:30 PM
#3421   Usually right after I sell. IRAHopeful 08/13/18 03:22:33 PM
#3420   I wonder where the bottom is. EponymousKook 08/13/18 11:51:44 AM
#3419   And management who has a clue. buckysherm 08/12/18 05:06:34 PM
#3418   Just watching and waiting... thefamilyman 08/12/18 03:17:18 PM
#3417   :-( buckysherm 08/12/18 08:28:59 AM
#3416   I scared everyone away. ?? buckysherm 08/12/18 08:28:35 AM
#3415   “Bristol Myers is actively looking for acquisitions in buckysherm 08/10/18 08:18:09 AM
#3414   http://cnafinance.com/opinion-adam-who/3449 buckysherm 08/09/18 02:45:31 PM
#3413   Everybody else shuts up and disappears after I buckysherm 08/08/18 08:01:53 PM
#3412   Great site : www.nashbiotechs.com Projects about $5Billion buckysherm 08/08/18 02:38:45 PM
#3411   The Stock Twits board is busy buckysherm 08/03/18 03:53:35 PM
#3410   Test $5 support, let’s see if it holds trding 07/30/18 03:50:39 PM
#3409   Short term $4 is a given, $3.50 is possible. buckysherm 07/27/18 01:57:38 PM
#3408   Short term $5 is a given, $4 is buckysherm 07/26/18 06:01:47 PM
#3407   Thanks for this post, Fred. EponymousKook 07/17/18 09:23:51 PM
#3406   That would be great so we can load MrGuru 07/16/18 07:58:09 PM
#3405   A couple weeks back someone said GALT was buckysherm 07/16/18 10:47:42 AM
#3404   Didja see the news on the old stock buckysherm 07/12/18 09:09:29 PM
#3403   Awesome ! Thanks for posting. Although buckysherm 07/12/18 08:04:25 AM
#3402   Thanks BugStocks, interesting article, mainly because it depicts MrGuru 07/12/18 07:04:19 AM
#3401   ARTICLE: http://psinvestor.com/galectin-blocker-is-front-runner-in-fight-against BugStocks_com 07/12/18 12:14:53 AM
#3400   I needs to be remembered that GALT failed MrGuru 07/11/18 08:20:24 AM
#3399   Here is a link to 1,300+ research articles buckysherm 07/10/18 10:27:40 AM
#3398   See the comments on the article - some Amatuer17 07/08/18 04:08:47 PM
#3397   Buying puts is better Drigue 07/06/18 12:18:25 PM
#3396   I should short stocks, because stocks always drop buckysherm 07/06/18 11:45:52 AM
#3395   How is the development of a subcutaneous or buckysherm 07/06/18 09:37:49 AM
#3394   Missed it by one day. Testing a trding 07/06/18 09:20:52 AM
#3393   Oh, sure ... gap up when I want buckysherm 07/06/18 09:18:16 AM
#3392   Nice GAP premarket! BugStocks_com 07/06/18 08:27:50 AM
#3391   Solid article - more gains coming Chess Master 07/06/18 03:28:11 AM
#3390   You cannot even compare - You will see Amatuer17 07/05/18 06:41:42 PM
#3389   Interesting. This might be a more promising buckysherm 07/05/18 04:36:38 PM
#3388   GALT Article: Galectin Therapeutics IPF Patent Solidifies Platform BugStocks_com 07/05/18 03:47:51 PM
#3387   One thing I would add. Which some would jimmy667 06/29/18 10:39:16 PM
#3386   Not yet. But watching. I hate bull trap jimmy667 06/29/18 10:29:08 PM
#3385   There are those who say that GALT’s “sketchy thefamilyman 06/27/18 07:02:59 PM
#3384   Thanks for that report dwntik5454 06/27/18 12:34:41 PM
#3383   Updated this review of the bull and bear cases: fred198484 06/27/18 12:08:56 PM
#3382   https://www.zacks.com/stock/news/309189/is-the-options-market-predicting-a-spike dwntik5454 06/27/18 10:41:33 AM
#3381   It’s now up $1.14 from yesterday’s close. thefamilyman 06/27/18 10:25:49 AM
#3380   Good summation. I am a buyer whence the jimmy667 06/26/18 11:14:41 PM
#3379   Very good analysis - one can decide which Amatuer17 06/26/18 06:54:36 PM
#3378   The bull case on GALT is simply stated fred198484 06/26/18 04:35:46 PM
#3377   Looks like a buy down here. Sorry to jimmy667 06/21/18 02:51:40 PM
#3376   Great article! Thanks for sharing. “Glad the volume is thefamilyman 06/21/18 01:26:46 PM
PostSubject